Data from EMA (European Medicines Agency) - Curated by EPG Health - Last updated 06 April 2018

Indication(s)

Zoledronic Acid Hospira 4 mg/5 ml concentrate for solution for infusion
Zoledronic Acid Hospira 4 mg/100 ml solution for infusion:

- Prevention of skeletal related events (pathological fractures, spinal compression, radiation or surgery to bone, or tumour-induced hypercalcaemia) in adult patients with advanced malignancies involving bone.
- Treatment of adult patients with tumour-induced hypercalcaemia (TIH).


Zoledronic Acid Hospira 5 mg/100 ml solution for infusion:
Treatment of Paget's disease of the bone in adults.

Full Prescribing information

Learning Zones

An epgonline.org Learning Zone (LZ) is an area of the site dedicated to providing detailed self-directed medical education about a disease, condition or procedure.

Chronic Lymphocytic Leukaemia (CLL)

Chronic Lymphocytic Leukaemia (CLL)

Refine your knowledge of chronic lymphocytic leukaemia (CLL) with information on pathophysiology, diagnosis, treatment options and more

+ 1 more

Migraine Knowledge Centre

Migraine Knowledge Centre

The Migraine Knowledge Centre features latest research on the prevalence and impact of migraine, the proposed neurological basis of the condition (and how this is being translated into new and exciting drug therapies), as well as current patient care strategies collated from headache organisations worldwide.

Chronic Obstructive Pulmonary Disease (COPD)

Chronic Obstructive Pulmonary Disease (COPD)

View highlights from recent congresses presented in new expert videos with leading physicians.

+ 7 more

Load more

Related Content

More information

Category Value
Agency product number EMEA/H/C/002365
Orphan designation No
Date First Approved 19-11-2012
Type Medicinal product subject to restricted medical prescription
Marketing authorisation holder Hospira UK Ltd